Camille Cisterne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camille Cisterne has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Pagin
CHU Lille, Service de Toxicologie et Génopathies, 59000 Lille, France
1 shared publication - Alexandra Masson
Department of Pediatrics, CHU Limoges, Limoges, France
1 shared publication - Ania Carsin
Department of Pediatrics, CH Saint Joseph, Marseille, France
1 shared publication - Antoine Deschildre
Service de Pneumologie et d'Allergologie Pédiatrique Hôpital Jeanne de Flandre, Univ. Lille, CHU de Lille Lille France
1 shared publication - Caroline Thumerelle
Pediatric Pulmonology Department University Hospital Lille France
1 shared publication - Charlotte Roy
Department of Paediatric Pulmonology and Allergology, University Hospital Necker-Enfants Malades, AP-HP, Université Paris Cité, France
1 shared publication
Latest Publications
- Open Access
- 26 February 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (1) , 11
Exposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes
CFTR modulators have transformed the clinical evolution of patients with CF. The number of pregnancies is increasing in women with CF, most of whom are now treated with CFTR modulators such as elexacaftor/tezacaftor/ivacaftor (ETI) or Tezacaftor/Ivacaftor. This raises some questions as we still lack data on foetal and maternal safety. The preliminary data seem to support the continuation of modulators. Some of these mothers may also give birth to newborns with CF and this raises more questions. We report here four cases of CF newborns whose mothers were treated with CFTR modulators throughout pregnancy to help refine potential foetal outcomes of in utero administration of CF modulators. No maternal or foetal complications could be attributed to CFTR modulators. Three CF newborns were exposed to ETI and were false negative of the newborn screening. Two of them were pancreatic sufficient at birth. The remaining patient, exposed to Tezacaftor/Ivacaftor (TI) alone, showed elevated immunoreactive trypsin (IRT) and severe pancreatic insufficiency at birth. These cases highlight that in utero administration of ETI could potentially improve neonatal outcomes of CF newborns and cause newborn screening false negative.
- 26 February 2026
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 12 (1) , 11
Open AccessExposure to CFTR Modulators During Pregnancy in Cystic Fibrosis: Four Cases to Highlight Neonatal Diagnostic Challenges and Outcomes
CFTR modulators have transformed the clinical evolution of patients with CF. The number of pregnancies is increasing in women with CF, most of whom are now treated with CFTR modulators such as elexacaftor/tezacaftor/ivacaftor (ETI) or Tezacaftor/Ivacaftor. This raises some questions as we still lack data on foetal and maternal safety. The preliminary data seem to support the continuation of modulators. Some of these mothers may also give birth to newborns with CF and this raises more questions. We report here four cases of CF newborns whose mothers were treated with CFTR modulators throughout pregnancy to help refine potential foetal outcomes of in utero administration of CF modulators. No maternal or foetal complications could be attributed to CFTR modulators. Three CF newborns were exposed to ETI and were false negative of the newborn screening. Two of them were pancreatic sufficient at birth. The remaining patient, exposed to Tezacaftor/Ivacaftor (TI) alone, showed elevated immunoreactive trypsin (IRT) and severe pancreatic insufficiency at birth. These cases highlight that in utero administration of ETI could potentially improve neonatal outcomes of CF newborns and cause newborn screening false negative.
- Open Access
- 25 December 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (3) , 685-692.e8
Development and Validation of a Questionnaire Measuring Treatment Burden in Pediatric Asthma
- 25 December 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (3) , 685-692.e8
Open AccessDevelopment and Validation of a Questionnaire Measuring Treatment Burden in Pediatric Asthma
- Open Access
- 1 September 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (1) , 68-71
Children Allergic to Peanut and/or Tree Nuts Are at Risk of Accidental Allergic Reactions
- 1 September 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (1) , 68-71
Open AccessChildren Allergic to Peanut and/or Tree Nuts Are at Risk of Accidental Allergic Reactions